Kiniksa Pharmaceuticals, Ltd. provided revenue guidance for 2023. Kiniksa now expects 2023 ARCALYST net product revenue of between $220 million and $230 million compared to prior guidance of between $200 million and $215 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.58 USD | +0.26% | -2.05% | +11.63% |
23/04 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
23/04 | Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.63% | 138.9Cr | |
+5.66% | 11TCr | |
+11.23% | 11TCr | |
-2.56% | 2.19TCr | |
-12.15% | 2.23TCr | |
-7.66% | 1.86TCr | |
-36.52% | 1.81TCr | |
-10.09% | 1.7TCr | |
+3.33% | 1.37TCr | |
+36.58% | 1.24TCr |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for 2023